NZ593653A - Treatment of inflammatory bowel diseases with mammal beta defensins - Google Patents

Treatment of inflammatory bowel diseases with mammal beta defensins

Info

Publication number
NZ593653A
NZ593653A NZ593653A NZ59365309A NZ593653A NZ 593653 A NZ593653 A NZ 593653A NZ 593653 A NZ593653 A NZ 593653A NZ 59365309 A NZ59365309 A NZ 59365309A NZ 593653 A NZ593653 A NZ 593653A
Authority
NZ
New Zealand
Prior art keywords
treatment
inflammatory bowel
bowel diseases
beta defensins
mammal beta
Prior art date
Application number
NZ593653A
Other languages
English (en)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holse Mygind
Karoline Sidelmann Brinch
Soeren Kjaerulff
Birgitte Andersen
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ593653(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of NZ593653A publication Critical patent/NZ593653A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ593653A 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins NZ593653A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4

Publications (1)

Publication Number Publication Date
NZ593653A true NZ593653A (en) 2012-09-28

Family

ID=41530820

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4
NZ593653A NZ593653A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4

Country Status (20)

Country Link
US (4) US8232242B2 (zh)
EP (2) EP2399600A1 (zh)
JP (2) JP2011528333A (zh)
KR (1) KR20110092325A (zh)
CN (2) CN102159233A (zh)
AP (2) AP2011005755A0 (zh)
AR (2) AR072032A1 (zh)
AU (1) AU2009272681A1 (zh)
BR (2) BRPI0915973A2 (zh)
CA (2) CA2730789A1 (zh)
CL (1) CL2011000099A1 (zh)
EA (2) EA201170219A1 (zh)
IL (2) IL210715A0 (zh)
MX (1) MX2011000568A (zh)
NZ (2) NZ590468A (zh)
PH (1) PH12012501542A1 (zh)
SG (1) SG172709A1 (zh)
TW (2) TW201004640A (zh)
WO (1) WO2010007166A2 (zh)
ZA (1) ZA201100461B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320929B1 (en) * 2008-07-18 2019-05-29 Defensin Therapeutics ApS Human beta defensins for use in the treatment of inflammatory diseases
EP2320928B1 (en) * 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with human beta defensins
BRPI0915973A2 (pt) 2008-07-18 2013-05-07 Novozymes Adenium Biotech As uso de uma beta defensina humana
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
ES2637286T3 (es) * 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
JP2019514908A (ja) * 2016-04-29 2019-06-06 ディフェンシン セラピューティクス エーピーエス 肝臓、胆管および膵臓の障害の治療
JP2020512287A (ja) 2016-12-13 2020-04-23 ディフェンシン セラピューティクス エーピーエス 肺の炎症性疾患を処置するための方法
EP3706773A2 (en) 2017-11-10 2020-09-16 Defensin Therapeutics ApS Maturation of mucosal defense and gut/lung function in the preterm infant
RU2020116903A (ru) 2017-11-24 2021-12-24 Дефенсин Терапьютикс Апс Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
JP2006514106A (ja) * 2002-12-19 2006-04-27 ヒルマン，イチャク 抗菌ペプチド阻害剤による疾患治療
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
CA2699163A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2320929B1 (en) 2008-07-18 2019-05-29 Defensin Therapeutics ApS Human beta defensins for use in the treatment of inflammatory diseases
BRPI0915973A2 (pt) 2008-07-18 2013-05-07 Novozymes Adenium Biotech As uso de uma beta defensina humana
EP2320928B1 (en) 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with human beta defensins
ES2637286T3 (es) 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide

Also Published As

Publication number Publication date
US8802621B2 (en) 2014-08-12
US20140135258A1 (en) 2014-05-15
WO2010007166A2 (en) 2010-01-21
EP2320930A2 (en) 2011-05-18
BRPI0915973A2 (pt) 2013-05-07
US8232242B2 (en) 2012-07-31
CN102159233A (zh) 2011-08-17
EA201170219A1 (ru) 2011-08-30
IL213680A0 (en) 2011-07-31
US20110251139A1 (en) 2011-10-13
BRPI0924481A2 (pt) 2015-08-11
IL210715A0 (en) 2011-03-31
JP2011528333A (ja) 2011-11-17
ZA201100461B (en) 2014-03-26
AR081948A2 (es) 2012-10-31
US20100016230A1 (en) 2010-01-21
TW201004640A (en) 2010-02-01
PH12012501542A1 (en) 2015-11-09
CA2750727A1 (en) 2010-01-21
NZ590468A (en) 2012-06-29
EP2399600A1 (en) 2011-12-28
AP2011005538A0 (en) 2011-02-28
US9279010B2 (en) 2016-03-08
MX2011000568A (es) 2011-02-23
KR20110092325A (ko) 2011-08-17
AU2009272681A1 (en) 2010-01-21
AR072032A1 (es) 2010-07-28
WO2010007166A3 (en) 2010-06-03
CL2011000099A1 (es) 2011-10-07
CN102247591A (zh) 2011-11-23
SG172709A1 (en) 2011-07-28
US20120309678A1 (en) 2012-12-06
JP2011225596A (ja) 2011-11-10
TW201138810A (en) 2011-11-16
AP2011005755A0 (en) 2011-06-30
CA2730789A1 (en) 2010-01-21
EA201100910A1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
NZ593653A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
TR201818927T4 (tr) Kataterlerde İyileştirme
IL200338A (en) Treatment of inflammatory diseases with the help of placental stem cells
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
IL220613B (en) Use of antibiotics and a probiotic formulation in the preparation of a drug for the treatment of inflammatory bowel disease
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
PT2510916T (pt) Composição farmacêutica antisséptica para a higiene oral e o tratamento de doenças bucais de origem microbiana
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
NZ589445A (en) Rasagiline for parkinson's disease modification
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
AP2011005537A0 (en) Treatment of inflammatory diseases with mammal beta defensins.
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
SG169332A1 (en) Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases
ZA201106056B (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
EA201170873A1 (ru) Безопасное введение десмопрессина
HUP0800498A2 (en) Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
CY1108501T1 (el) Συνθεση δια την προληψη και θεραπευτικη αγωγη ασθενειων κρυολογηματος
NZ597675A (en) Medicament for the long term nsaid use
IL216717A (en) Use of benzidamine in the manufacture of a drug for the treatment of p40-dependent diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed